[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605500":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":11,"centralContacts":32,"locations":38,"responsibleParty":179,"collaborators":11,"id":181,"slug":182,"hasResults":183,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":11,"eligibilityCriteria":187,"healthyVolunteers":183,"sex":188,"minAge":189,"maxAge":11,"enrollmentInfo":190,"targetDuration":11,"studyType":193,"phases":194,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":41,"whyStopped":11,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":210},{"fullName":5,"class":6},"Epics Therapeutics","INDUSTRY",[8,14,17,20,23],{"label":9,"type":10,"description":11,"interventionNames":12},"EP102 Dose level 1","EXPERIMENTAL",null,[13],"Drug: EP102",{"label":15,"type":10,"description":11,"interventionNames":16},"EP102 Dose level 2",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"EP102 Dose level 3",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"EP102 Dose level 4",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"EP102 Dose level 5",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"DRUG","EP102","EP102 will be administered orally",[9,15,18,21,24],[33],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},"Clinical Trial Liaison","CONTACT","+32 71 348 500","info@epicstx.com",[39,56,65,77,89,103,115,129,141,155,167],{"facility":40,"status":41,"city":42,"state":11,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Institut Jules Bordet","RECRUITING","Brussels","1070","Belgium","BE",{"type":47,"coordinates":48},"Point",[49,50],4.34878,50.85045,{"lat":50,"lon":49},[53],{"name":54,"role":35,"phone":55,"phoneExt":11,"email":37},"Principal investigator","+32 2 541 31 11",{"facility":57,"status":41,"city":42,"state":11,"zip":58,"country":44,"countryCode":45,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},"Cliniques universitaires Saint-Luc","1200",{"type":47,"coordinates":60},[49,50],{"lat":50,"lon":49},[63],{"name":54,"role":35,"phone":64,"phoneExt":11,"email":37},"+32 2 764 11 11",{"facility":66,"status":41,"city":67,"state":11,"zip":68,"country":44,"countryCode":45,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Universitair Ziekenhuis Gent (UZ Gent) - Drug Research Unit Gent (DRUG)","Ghent","9000",{"type":47,"coordinates":70},[71,72],3.71667,51.05,{"lat":72,"lon":71},[75],{"name":54,"role":35,"phone":76,"phoneExt":11,"email":37},"+ 32 9 332 00 00",{"facility":78,"status":41,"city":79,"state":11,"zip":80,"country":44,"countryCode":45,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Leuven Cancer Institute (LKI)","Leuven","3000",{"type":47,"coordinates":82},[83,84],4.70093,50.87959,{"lat":84,"lon":83},[87],{"name":54,"role":35,"phone":88,"phoneExt":11,"email":37},"+ 32 16 34 13 68",{"facility":90,"status":41,"city":91,"state":11,"zip":92,"country":93,"countryCode":11,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Masaryk Memorial Cancer Institute","Brno","656 53","Czechia",{"type":47,"coordinates":95},[96,97],16.60796,49.19522,{"lat":97,"lon":96},[100],{"name":101,"role":35,"phone":102,"phoneExt":11,"email":37},"Principal Investigator","+420 543 131 111",{"facility":104,"status":41,"city":105,"state":11,"zip":106,"country":93,"countryCode":11,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Olomouc University Hospital","Olomouc","77900",{"type":47,"coordinates":108},[109,110],17.25175,49.59552,{"lat":110,"lon":109},[113],{"name":101,"role":35,"phone":114,"phoneExt":11,"email":37},"+420 585 851 111",{"facility":116,"status":41,"city":117,"state":11,"zip":118,"country":119,"countryCode":120,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Netherlands Cancer Institute (NKI)","Amsterdam","1066 CX","Netherlands","NL",{"type":47,"coordinates":122},[123,124],4.88969,52.37403,{"lat":124,"lon":123},[127],{"name":54,"role":35,"phone":128,"phoneExt":11,"email":37},"+31 20 512 9111",{"facility":130,"status":41,"city":131,"state":11,"zip":132,"country":119,"countryCode":120,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"University Medical Center Groningen, University of Groningen Department of Medical Oncology","Groningen","9713 GZ",{"type":47,"coordinates":134},[135,136],6.56667,53.21917,{"lat":136,"lon":135},[139],{"name":101,"role":35,"phone":140,"phoneExt":11,"email":37},"+31 50 361 28 21",{"facility":142,"status":41,"city":143,"state":11,"zip":144,"country":145,"countryCode":146,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Hospital Universitari Vall d'Hebron - Vall d'Hebron Institute of Oncology","Barcelona","8035","Spain","ES",{"type":47,"coordinates":148},[149,150],2.15899,41.38879,{"lat":150,"lon":149},[153],{"name":101,"role":35,"phone":154,"phoneExt":11,"email":37},"+34 932 54 34 50",{"facility":156,"status":41,"city":157,"state":11,"zip":158,"country":145,"countryCode":146,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"START Madrid - CIOCC","Madrid","28050",{"type":47,"coordinates":160},[161,162],-3.70256,40.4165,{"lat":162,"lon":161},[165],{"name":101,"role":35,"phone":166,"phoneExt":11,"email":37},"+34 91 756 78 25",{"facility":168,"status":41,"city":169,"state":11,"zip":170,"country":145,"countryCode":146,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Hospital Universitario de Santiago de Compostela","Santiago de Compostela","15706",{"type":47,"coordinates":172},[173,174],-8.54569,42.88052,{"lat":174,"lon":173},[177],{"name":54,"role":35,"phone":178,"phoneExt":11,"email":37},"+34 981 95 00 00",{"type":180,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100605500","phase-1-ep102-safety-and-efficacy-in-mettl3-modulation-in-advanced-solid-tumors-100605500",false,"NCT07163325","EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors","A Phase 1 Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered EP102 Monotherapy in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Participants must have a histological diagnosis of locally advanced or metastatic malignant solid tumors of one of the following cancer types:\n\n  * ovarian cancer\n  * cervical cancer\n  * endometrial cancer\n  * testicular cancer\n  * cholangiocarcinoma\n  * thyroid cancer\n  * parathyroid cancer\n  * adrenal cancer\n  * pancreatic cancer\n  * non-small-cell lung cancer (NSCLC)\n  * head-and neck cancer\n  * renal cell cancer\n  * urethral cancer\n  * bladder cancer\n  * colorectal cancer\n  * gastric cancer\n  * esophageal cancer\n  * triple-negative breast cancer\n  * thymoma\n  * soft tissue sarcoma\n* Participants must have failed (i.e. progressed on, or been intolerant to standard treatment), or no standard treatment must exist, or they must have refused standard treatment. All participants must have received at least one prior line of systemic therapy.\n* Participants must have at least one measurable lesion per RECIST v1.1.\n* Participant must have a life expectancy of at least 12 weeks.\n\nExclusion Criteria:\n\n* Participants with an active severe infection or unexplained fever \\> 38.5°C during screening or on the first day of study drug administration are excluded. However, at the Investigator's discretion, participants with tumor-related fever may be enrolled.\n* Participants with known human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) infection (hepatitis B surface antigen (HBsAg) positive in serum), or active hepatitis C virus (HCV) infection (HCV RNA positive in serum).\n* Participants with known dysphagia, short-bowel syndrome, gastroparesis, or any condition that may impair the ingestion or gastrointestinal absorption of orally administered drugs.\n* Pregnant or breastfeeding participants.\n* Participants who have received IMP or devices in other clinical trials within four weeks before the first dose.\n* Participants with prior exposure to selective METTL3 inhibitor therapy.","ALL","18 Years",{"count":191,"type":192},48,"ESTIMATED","INTERVENTIONAL",[195],"PHASE1","This the first-in-human (FIH) study for the Investigational Medicinal Product (IMP) EP102, is designed to explore the maximum tolerated dose (MTD), the overall safety profile, its pharmacokinetic (PK) \u002F pharmacodynamic (PD) profile, and an exploratory evaluation of antitumor activity in participants with advanced solid tumors, who have no available standard therapy or who have failed standard therapies.\n\nThis study will inform on recommended doses for further studies, e.g. dose optimization studies and \u002F or efficacy and safety studies.",[198],"Advanced Solid Tumor (Phase 1)",[200,29],"Advanced Solid Tumors","2026-06-10",{"date":203,"type":204},"2026-06-11","ACTUAL",{"date":206,"type":204},"2025-07-24",{"date":208,"type":192},"2028-11",{"name":5,"class":6},11]